I wouldn't be getting anyone's panties in a wad over Prosensa's "lipstick on a pig" attempt to drum up interest at JPM. Remember:
1) They never even made their Phase II results public. Yeah, that's promising.
2) The list of dangerous side effects is long and extends well beyond the well known renal toxicity/necrosis. This has been discussed at length on these boards some months ago.
3) Ian Estepan, a fund manager, tweeted last night that the strongest advocates for early approval of SRPT's eteplirsen are the parents of children in the Prosensa trial. He emphasized that he was not joking. That's how bad the side effects are.
Prosensa is holding a losing hand: an unsafe, unapprovable drug, whose dosing they can't even figure out. Like any company, they are desperately trying to stay above water by hiding their problems (in fact, hiding their full clinical results) in order to raise money.